Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have earned an average rating of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $48.3636.

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Piper Sandler restated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Roth Mkm restated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a report on Friday, May 15th. Finally, Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $26.16 on Thursday. The business’s fifty day moving average price is $31.18 and its two-hundred day moving average price is $26.87. The stock has a market cap of $1.51 billion, a PE ratio of -11.28 and a beta of 0.39. Capricor Therapeutics has a one year low of $4.30 and a one year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts predict that Capricor Therapeutics will post -0.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other news, Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the sale, the director owned 7,529 shares in the company, valued at $240,928. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. This trade represents a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 172,529 shares of company stock worth $5,302,440 in the last 90 days. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth about $43,000. KBC Group NV acquired a new position in Capricor Therapeutics in the first quarter worth about $44,000. GoalVest Advisory LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth about $59,000. Finally, Tower Research Capital LLC TRC grew its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.